文献速递胸部肿瘤

索托拉西布联合卡铂和培美曲塞治疗KRAS G12C突变晚期非鳞状非小细胞肺癌的单臂2期研究(WJOG14821L,SCARLET)

A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET).
PubMed 文献 · J Thorac Oncol · 2025-01-17

SCARLET是一项单臂2期研究,纳入30例初治KRAS G12C突变非鳞状非小细胞肺癌患者,接受索托拉西布960 mg每日联合4周期卡铂(AUC=5)/培美曲塞500 mg/m2,随后索托拉西布/培美曲塞维持至疾病进展。客观缓解率为88.9%(95%CI 70.8%-97.6%),中位无进展生存期6.6个月,中位总生存期20.6个月,毒性可控。

要点

  • 索托拉西布联合卡铂/培美曲塞在KRAS G12C突变非鳞状非小细胞肺癌中客观缓解率达88.9%。
  • PD-L1表达低于1%的患者客观缓解率为100%,中位无进展生存期9.7个月。
  • 基线无KRAS G12C、无KRAS通路共突变或3周时清除KRAS G12C的患者中位无进展生存期更优。

核心结论

  • 在KRAS G12C突变非鳞状非小细胞肺癌患者中,索托拉西布联合卡铂/培美曲塞显示出有利的疗效,尤其是PD-L1表达低于1%的患者,且毒性可控。

研究设计与样本

  • SCARLET为单臂2期研究,纳入初治KRAS G12C突变非鳞状非小细胞肺癌患者,2021年10月至2022年7月共入组30例。
  • 参与者接受索托拉西布960 mg每日联合4周期卡铂(曲线下面积=5)/培美曲塞500 mg/m2,随后索托拉西布/培美曲塞维持至疾病进展。
  • 主要终点为客观缓解率,次要终点为无进展生存期、总生存期和安全性;基线、3周及疾病进展时进行血浆二代测序。

主要发现

  • 中位随访14.8个月,客观缓解率为88.9%(80%CI 78.5%-94.8%,95%CI 70.8%-97.6%)。
  • 中位无进展生存期为6.6个月(95%CI 5.3-16.7个月),中位总生存期为20.6个月(95%CI 8.1个月-未估计)。
  • PD-L1表达≥1%和<1%的患者客观缓解率分别为82.3%和100%,中位无进展生存期分别为7.6个月和9.7个月。
  • 基线无KRAS G12C、无KRAS相关通路共突变或3周时清除KRAS G12C的患者中位无进展生存期分别为16.7、13.9、8.7个月。
  • 获得性耐药中检测到肿瘤蛋白53突变及EGFR和MET扩增。

关键数值与推荐

  • 客观缓解率88.9%(80%CI 78.5%-94.8%,95%CI 70.8%-97.6%)。
  • 中位无进展生存期6.6个月(95%CI 5.3-16.7个月),中位总生存期20.6个月(95%CI 8.1个月-未估计)。
  • PD-L1≥1%组客观缓解率82.3%、中位无进展生存期7.6个月;PD-L1<1%组客观缓解率100%、中位无进展生存期9.7个月。
  • 基线无KRAS G12C组中位无进展生存期16.7个月;无KRAS相关通路共突变组13.9个月;3周时清除KRAS G12C组8.7个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The efficacy and safety of sotorasib plus platinum doublet chemotherapy in KRAS G12C-mutated nonsquamous NSCLC (nonsq NSCLC) have been previously reported with a limited follow-up period. METHODS: SCARLET is a single-arm phase 2 study involving chemotherapy-naive patients with KRAS G12C-mutated nonsq NSCLC. The participants received 960 mg daily plus four cycles of carboplatin (area under the curve = 5)/pemetrexed 500 mg/m2, followed by sotorasib/pemetrexed until disease progression. The primary end point was the overall response rate (ORR) and the secondary end points were progression-free survival (PFS), overall survival, and safety. Using plasma samples, next-generation sequencing was performed at baseline, 3 weeks, and during disease progression (the Japan Registry of Clinical Trials number 2051210086). RESULTS: Thirty patients were enrolled between October 2021 and July 2022 with a median follow-up of 14.8 months. ORR was 88.9% (80% confidence interval [CI]: 78.5%-94.8%, 95% CI: 70.8%-97.6%), median PFS was 6.6 months (95% CI: 5.3-16.7 mo), and median overall survival was 20.6 months (95% CI: 8.1 mo-not estimated). Among patients with programmed death-ligand 1 expression levels of 1% or higher and less than 1%, the ORRs were 82.3 and 100%, respectively, and the median PFS was 7.6 and 9.7 months, respectively. Using plasma samples, patients without KRAS G12C at baseline, without KRAS-related pathway co-alterations, or who cleared KRAS G12C at 3 weeks had better median PFS (16.7, 13.9, 8.7 mo, respectively). Tumor protein 53 mutations and EGFR and MET amplification were detected as acquired resistance. CONCLUSIONS: In patients with KRAS G12C-mutated nonsq NSCLC, sotorasib plus carboplatin/pemetrexed reported favorable efficacy, particularly for patients with less than 1% programmed death-ligand 1, with manageable toxicity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Akamatsu H, Sakata S, Azuma K, et al. A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET). J Thorac Oncol. 2025. PMID: 39828218. doi:10.1016/j.jtho.2025.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。